Search Results - "Reyentovich, A"

Refine Results
  1. 1

    Cardiac Allograft Vasculopathy in Heart Transplant Recipients from Hepatitis C Viremic Donors by Kadosh, B., Gidea, C., Reyentovich, A., Razzouk, L., Smith, D., Katz, S., Saraon, T., Rao, S., Goldberg, R., Moazami, N.

    “…Heart transplantation from Hepatitis C (HCV) viremic donors is becoming increasingly used due to advent of direct acting antiviral drugs with almost 100% cure…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Incidence of Acute Cellular Rejection in Heart Transplant Recipients from Hepatitis C Viremic Donors – One-Year Follow-Up by Stachel, M.W., Gidea, C.G., Katz, S., Narula, N., Reyentovich, A., Smith, D., Saraon, T., Rao, S., Goldberg, R., Moazami, N.

    “…Passive transmission of hepatitis C (HCV) viremia from actively infected donors to uninfected recipients at the time of heart transplantation may modulate…”
    Get full text
    Journal Article
  4. 4

    Safety and Feasibility of Tilt Table Protocol for Early Mobilization of Patients with Femoral Intra-Aortic Balloon Pumps by Fischer, M.G., Chan, W., Saputo, M., Piper, G., Chen, S., Toy, B., Reyentovich, A., Gidea, C., Kon, Z., Moazami, N., Smith, D.E.

    “…Intra-aortic balloon pumps (IABPs) can be used to provide hemodynamic support in patients with end-stage heart failure. IABPs are commonly inserted via the…”
    Get full text
    Journal Article
  5. 5

    Magnitude of Viremia after Heart and Lung Transplantation from HCV Viremic Donors and Time to Clearance Based on Timing of Starting Therapy Post-Transplantation by Chen, S., Gidea, C., Angel, L., Reyentovich, A., Kon, Z., Smith, D., Sureau, K., Pavone, J., Lewis, T., Winston, B., Moazami, N.

    “…Thoracic organ transplantation from Hepatitis C (HCV) viremic donors is a promising strategy due to curative therapies for HCV. Currently, there is no…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Primary Graft Dysfunction After Heart Transplantation: Incidence and Current Risk Factors by Chen, S., Ostberg, N.P., Carillo, J.A., Gidea, C., Reyentovich, A., Galloway, A.C., Moazami, N., Smith, D.E.

    “…Primary graft dysfunction (PGD) is a leading cause of perioperative mortality in heart transplant (HT). Yet the impact of the current increased use of…”
    Get full text
    Journal Article
  17. 17

    Effect of Glecaprevir-Pibrentasvir on Tacrolimus Dosage Requirements in Cardiac Transplant Recipients by Lewis, T.C., Gidea, C., Reyentovich, A., Moazami, N.

    “…Heart transplantation (HTx) from hepatitis C virus (HCV) positive donors to HCV negative recipients may reduce waitlist time and increase access to viable…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Defining the Normal Values for Left Ventricular Global Longitudinal Strain in Adult Heart Transplanted Patients by Sikand, N.V., Maidman, S., Saric, M., Reyentovich, A., Saraon, T., Rao, S., Katz, S., Goldberg, R., Kadosh, B., DiVita, M., Cruz, J., Riggio, S., Moazami, N., Gidea, C.

    “…To date, there are no data about normal values of Global Longitudinal Strain (GLS) in adults post heart transplant. The GLS correlation with heart graft…”
    Get full text
    Journal Article
  20. 20